NCT06496113Completed
Robotic Versus Laparoscopic Liver Resection for Hepatocellular Carcinoma
Recurrence ad Survival After Robotic Versus Laparoscopic Liver Resection in Very-early to Early (BCLC 0-A) Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 11 Jul 2024
Brief summary (registry, in English)
The objective of the study is to investigate the long-term outcomes of minimally invasive liver surgery (robotic vs laparoscopic) for hepatocellular carcinoma patients of stage BCLC 0-A. Data from two tertiary centers for liver surgery will be retrospectively reviewed. Patients will be divided in two cohorts (robot; laparoscopy). The primary endpoint will be recurrence-free and overall survival; secondary endpoints were incidence, pattern, and treatment of recurrences.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 196 (actual)
- First submitted
- 1 Jul 2024
- Start date
- Jan 2014
- Primary completion date
- Apr 2024
- Lead sponsor
- Ente Ospedaliero Cantonale, Bellinzona
- NCT number
- NCT06496113
What you commit to
- Study type: Observational
- Participants enrolled: 196
- From Jan 2014 to the primary completion date, Apr 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Non-elective surgery
- Intraoperative switch to locoregional therapies (like radiofrequency or microwave ablation)
Other
- Hand-assisted procedures
- Non-histologically confirmed HCC
- Mixed hepato-cholangiocarcinoma.
Who the study is looking for
- Patients undergoing robotic and laparoscopic resections
- Histology-confirmed HCC of stage BCLC 0-A
- Preserved liver function (Child score A-B)
- Patients \>18 years old
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.